Reviono, Widayanto, Harsini, Jatu Aphridasari, Yusup Subagio Sutanto
Background: Multidrug resistant tuberculosis (MDR TB) is known as threatening and challenging community health problem worldwide. Treatment of MDR TB is difficult because it needs higher cost, longer treatment period, and more adverse events than drug-sensitive TB. Hearing loss is a major adverse event due to aminoglycosides that commonly used as one of the regiments of MDR TB. Previous treatment of streptomycin may worsen the symptoms. The objective was to assess the correlation between streptomycin with incidence of hearing loss in MDR TB patients in Dr. Moewardi Hospital.
Methods : A cross sectional study was conducted by reviewing medical records and audiometry report in 33 patients (18 females and 15 males) who received standardized treatment for MDR TB from January 2011 to September 2012 in Programmatic Management of Drug Resistant Tuberculosis unit of Dr. Moewardi Hospital.
Results :Among 33 MDR TB patients, 57.6% experienced hearing loss as an adverse events of MDR treatment, and of 54.2% were MDR TB patients with treatment of streptomycin. The analysis showed there was no significant correlation between treatment of streptomycin and hearing loss, p=0.698. The earliest onset of hearing loss in MDR TB patients with treatment of streptomycin was occurred within the first month of treatment (15.4%).
Conclusion: Treatment of streptomycin has no correlation with incidence of hearing loss in MDR TB patients in Dr. Moewardi Hospital. (J Respir Indo. 2013; 33:167-72)